![Janneke Meulenberg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Janneke Meulenberg
Vorstandsvorsitzender bei ViciniVax BV
Aktive Positionen von Janneke Meulenberg
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ViciniVax BV
![]() ViciniVax BV Pharmaceuticals: OtherHealth Technology ViciniVax BV develops, commercializes, and markets vaccines for the treatment of cancer. It also develops therapies for cervical cancer. The company was founded by Toos Daemen, Hans Nijman, Alfred N. Nijkerk, Ate van der Zee, and Jan C. Wilschut in 2008 and is headquartered in Groningen, Netherlands. | Vorstandsvorsitzender | - | - |
MeiraGTx Netherlands BV
![]() MeiraGTx Netherlands BV Pharmaceuticals: MajorHealth Technology MeiraGTx Netherlands BV operates as a biopharmaceutical company developing local gene therapy for inflammatory diseases. It is into develop adeno-associated viral mediated gene therapy for patients with rheumatic conditions. The company was founded in 2005 and is headquartered in Amsterdam, the Netherlands. | Vorstandsvorsitzender | 01.11.2019 | - |
Karriereverlauf von Janneke Meulenberg
Ehemalige bekannte Positionen von Janneke Meulenberg
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ID-Lelystad Instituut Voor Dierhouderij En Diergezondheid BV
![]() ID-Lelystad Instituut Voor Dierhouderij En Diergezondheid BV Miscellaneous Commercial ServicesCommercial Services ID-Lelystad Instituut Voor Dierhouderij En Diergezondheid BV is a Dutch company that engages in research and development on livestock. The private company is based in Lelystad, Netherlands. | Corporate Officer/Principal | - | - |
Amsterdam Molecular Therapeutics (AMT) Holding NV
![]() Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Corporate Officer/Principal | 01.01.2000 | - |
Ausbildung von Janneke Meulenberg
University of Groningen | Undergraduate Degree |
University of Amsterdam | Doctorate Degree |
Statistik
International
Niederlande | 7 |
Operativ
Corporate Officer/Principal | 2 |
Chief Executive Officer | 2 |
Undergraduate Degree | 1 |
Sektoral
Consumer Services | 3 |
Commercial Services | 3 |
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
![]() Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
ID-Lelystad Instituut Voor Dierhouderij En Diergezondheid BV
![]() ID-Lelystad Instituut Voor Dierhouderij En Diergezondheid BV Miscellaneous Commercial ServicesCommercial Services ID-Lelystad Instituut Voor Dierhouderij En Diergezondheid BV is a Dutch company that engages in research and development on livestock. The private company is based in Lelystad, Netherlands. | Commercial Services |
ViciniVax BV
![]() ViciniVax BV Pharmaceuticals: OtherHealth Technology ViciniVax BV develops, commercializes, and markets vaccines for the treatment of cancer. It also develops therapies for cervical cancer. The company was founded by Toos Daemen, Hans Nijman, Alfred N. Nijkerk, Ate van der Zee, and Jan C. Wilschut in 2008 and is headquartered in Groningen, Netherlands. | Health Technology |
MeiraGTx Netherlands BV
![]() MeiraGTx Netherlands BV Pharmaceuticals: MajorHealth Technology MeiraGTx Netherlands BV operates as a biopharmaceutical company developing local gene therapy for inflammatory diseases. It is into develop adeno-associated viral mediated gene therapy for patients with rheumatic conditions. The company was founded in 2005 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
- Börse
- Insiders
- Janneke Meulenberg
- Erfahrung